Atwater Malick’s GSK GSK Stock Holding History

Atwater Malick’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-68	Closed	-$4K	–	104
2019 Q3	$4K	Buy	+68	New	+$3.5K	﹤0.01%	184

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Atwater Malick's GSK Position: Q4 2019 in Review

Atwater Malick sold out of GSK (GSK) in Q4 2019, closing a stake of 68 shares — an estimated $4K sold.

Atwater Malick first reported a position in GSK in Q3 2019 and held it in 1 quarter. The position peaked at $4K in Q3 2019. 894 funds tracked by Wall St. Rank hold GSK as of Q4 2019.

Atwater Malick reported no remaining GSK position as of Q4 2019 after selling out during the quarter.
Atwater Malick sold 68 GSK shares in Q4 2019, an estimated $4K.
Atwater Malick first reported a position in GSK in Q3 2019 and held it in 1 quarter.
Atwater Malick's GSK position peaked at $4K in Q3 2019.
894 funds tracked by Wall St. Rank held GSK as of Q4 2019.

Based on Atwater Malick's 13F filing for Q4 2019, filed 7 Jan 2020.